New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Urgent government calls for more high-powered sovereign computers to fulfil Swedish goal of building a more powerful AI ...

Soros Fund Management's 13F portfolio grew slightly to $6.70B in Q1 2025. Check out the significant new stakes and major ...

The PGIM Jennison Health Sciences Fund lost value, underperforming its benchmark Index during the Q1 of 2025. Click here to read the full commentary.

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

At the Data + AI Summit, Databricks announced the launch of Agent Bricks, a new offering that allows businesses to build and ...

The results, published in Nature Communications, point to what could be the most effective treatment to date for early-stage ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has ...